Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Lung Cancer Video Library - Spanish Language: Video #17 First Line Therapy for NSCLC Patients That Have Anaplastic Lymphoma Kinase (ALK) Positive
Anonymous
Terapia de primera línea para pacientes con cáncer pulmonar de células no pequeñas que presentan la cinasa de linfoma anaplásico (CLA) positiva.
For our 17th video in the GRACE Spanish Lung Cancer Library, 
Dr. Brian Hunis, Medical Director, Head and Neck Cancer Program, Memorial Cancer Institute, Miami, Florida, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis speaks about first line therapy for non-small cell lung cancer patients that have anaplastic lymphoma kinase (ALK) positive.
TRANSCRIPTS - Spanish and English
Terapia de primera línea para pacientes con cáncer pulmonar de células no pequeñas que presentan la cinasa de linfoma anaplásico (CLA) positiva.
En los pacientes en los cuales uno describe que el adenocarcinoma de pulmón de células no pequeñas tiene la translocación del gen ALK, hay terapia dirigida que atacan exclusivamente a las células que expresan esa mutación. Por lo cual los efectos adversos, la toxicidad y las respuestas son muchísimo mejores.
La primera terapia para pacientes con translocación en ALK que se ha usado en el mundo es con crisotinib. Crisotinib es una píldora que se toma diariamente, es bien tolerada y con efectos muy positivos.
First line therapy for non-small cell lung cancer patients that have the anaplastic lymphoma kinase positive.
In patients that have adenocarcinoma of non-small cells and also have the ALK gene translocation, there is a targeted treatment that only attacks the cell that express this mutation. So, the side effects, toxicity and the response are better.
The first therapy for patients with the ALK translocation that has been used in the world is with crisotinib. Crisotinib is a pill that is taken daily, is well tolerated and with very positive effects.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention.
To watch the complete playlist, click here.
Thanks to Regeneron and Daiichi-Sankyo.
Online Community
Dr. Singhi's reprise about appropriate treatment, "Right patient, right time, right team".
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.